The Klotho Protein and Longevity: From Mineral Metabolism to Cognitive Rejuvenation

1. Introduction: A Protein Named After Fate

In 1997 a mouse mutant was described that developed arteriosclerosis, osteoporosis, emphysema, infertility, and a markedly shortened lifespan. The disrupted gene was named Klotho, after the Greek Fate who spins the thread of life. The converse finding was equally striking: mice engineered to overexpress Klotho lived substantially longer than normal, and later work reported that Klotho administration improves cognition in aged and diseased brains. Few aging-related factors combine such a clear loss-of-function phenotype, such a clear gain-of-function phenotype, and such direct translational logic.

Klotho is now understood to exist in two principal forms — a membrane-bound protein that acts as a co-receptor, and a secreted protein that circulates as a hormone-like factor — with distinct functions. This article describes that biology, the evidence that Klotho declines with human age and predicts disease, and the state of therapeutic attempts to raise it. Claims are labelled established, emerging, hypothesis, or speculative.

2. Biology: Membrane Co-Receptor and Circulating Hormone

2.1. Membrane Klotho and the FGF23 Axis

The membrane-bound form of Klotho is an obligate co-receptor for fibroblast growth factor 23 (FGF23), a hormone produced by bone that governs phosphate homeostasis. FGF23 signals only when Klotho is present to form the receptor complex, principally in the kidney and parathyroid glands. This axis regulates renal phosphate excretion, calcium handling, and the activation of vitamin D.

The mechanism explains several features of the Klotho-deficient mouse: impaired phosphate excretion leads to hyperphosphatemia and soft-tissue calcification, and disturbed mineral metabolism weakens bone. It also explains why Klotho is a central factor in chronic kidney disease-mineral and bone disorder, in which FGF23 and Klotho are altered. Evidence: established.

2.2. Secreted Klotho as a Circulating Factor

The secreted form of Klotho circulates in blood and cerebrospinal fluid and appears to act as a hormone-like regulator with broad tissue effects. In model organisms it has been reported to suppress insulin and IGF-1 signalling — a pathway whose attenuation is associated with longevity in multiple species — and to modulate Wnt signalling, oxidative stress, and inflammation. These actions provide a mechanistic bridge between Klotho and several hallmarks of aging. Evidence: established in model organisms; the magnitude of each effect in humans is uncertain.

2.3. Klotho and the Brain

Klotho is expressed in the brain, and its secreted form has been linked to synaptic function, adult neurogenesis, and cognitive performance. Notably, in mouse studies, administering Klotho peripherally improved cognition even though it does not efficiently cross the blood-brain barrier, implying that it acts through one or more as-yet-unidentified systemic messengers. This observation is emerging and mechanistically unresolved: the phenomenon has been reported in animal models, but the intervening mechanism is not established, and the relevance to human cognition is hypothesis-level.

An important property of the secreted isoform is that, unlike the membrane form, it appears relatively well tolerated when overexpressed — one reason it has become the focus of therapeutic gene-transfer experiments.

3. Klotho and the Aging Human

3.1. Circulating Levels and Disease Associations

Circulating Klotho declines with age and falls further in chronic kidney disease. In observational cohorts, lower Klotho levels are associated with cardiovascular events, frailty, and cognitive decline. Because Klotho is also cleared by the kidney, some of these associations may partly reflect renal function rather than Klotho biology per se. Evidence: established associations; directionality and causality not established.

3.2. Genetic Variation

A common functional variant in the KLOTHO gene, known as KL-VS, has been associated in some studies with longevity, cardiovascular health, and better cognitive performance, and its effects have been reported to differ by sex and genotype. The findings are not consistently replicated across populations, and the effect sizes are modest. Evidence: emerging; some association, incomplete reproducibility.

3.3. Klotho as a Biomarker

Because Klotho tracks with age, frailty, and disease, it is sometimes proposed as a biomarker of biological age. This is an attractive idea but currently an emerging hypothesis. A useful biological-age biomarker must add predictive information beyond chronological age and beyond existing markers; demonstrating that requires large, prospective, multi-omic studies that have not yet been completed for Klotho.

4. Therapeutic Approaches

4.1. What the Mouse Data Show

The founding observations were that disrupting Klotho accelerates an aging-like phenotype and that overexpressing it extends lifespan. More recent work has moved from transgenic overexpression to testable delivery systems. In a 2025 study, a single adeno-associated virus (AAV9) dose that raised circulating secreted Klotho extended total longevity in male wild-type mice by approximately 20%, with improvements in muscle, bone, and hippocampal neurogenesis markers. The experiment also illustrates why translation is not straightforward: the effect was significant at the older treatment age but not at the younger one, and treated female mice developed health problems that prevented any conclusion about lifespan in females. The authors reported this as the first lifespan extension from s-Klotho gene therapy in healthy wild-type mice. Evidence: emerging (single study, modest group sizes, sex-specific effects).

4.2. Protein Replacement and Gene Therapy

Two therapeutic routes are being pursued. The first is recombinant protein — administering Klotho itself — which faces the usual obstacles of short circulating half-life, the need for repeated dosing, and poor access to the central nervous system. The second is gene therapy, delivering a gene so that the body produces secreted Klotho itself; this could in principle provide long-lasting single-dose expression, but raises the safety and durability questions common to gene therapy.

The first human studies are now beginning. A Phase 1 trial of an injectable plasmid-delivered Klotho gene therapy in healthy adults was registered in 2025, with cognitive and health endpoints and a small single-group design. Separately, a biotechnology company is developing AAV-based secreted-Klotho gene therapies for neurodegenerative indications (amyotrophic lateral sclerosis and Alzheimer’s disease), which received an orphan-drug designation in 2025. These are very early, safety-focused studies without results, and none addresses aging as an endpoint.

5. Prospects and the Translation Gap

Klotho is unusual in aging research in that it was discovered through phenotype rather than hypothesis: a genetic accident revealed a gene whose manipulation changes lifespan and multiple organ systems at once. That gives it strong biological credibility. The gap is entirely translational. There is currently no evidence in humans that raising Klotho slows aging, improves cognition, or extends life, and the first-in-human studies are designed to test safety and target engagement, not clinical benefit.

The most plausible near-term applications are narrower than «longevity»: chronic kidney disease-mineral and bone disorder, where the FGF23-Klotho axis is central, and specific neurodegenerative indications. Only if those programmes establish safety and measurable target engagement would broader evaluation in aging be justified. Statements that Klotho therapy will add a defined number of years of healthy life are, at present, speculative.

6. Limitations and Open Questions

• Assay and source ambiguity. Measuring «Klotho» in blood is complicated by multiple isoforms and by renal clearance; associations may partly reflect kidney function.
• Sex differences. Both genetic-association and gene-therapy studies report sex-dependent effects, the basis of which is not understood.
• Mechanism of the brain effect. How peripheral Klotho improves cognition without entering the brain remains unresolved.
• Delivery. Recombinant protein has poor pharmacokinetics and central-nervous-system access; gene therapy has durability and safety unknowns.
• No human efficacy data. Every therapeutic claim currently rests on animal models.

7. Conclusion

Klotho is one of the most biologically compelling targets in aging research, with a defined receptor function, a wide-ranging set of tissue effects, and reproducible lifespan and health effects in mice. It is also a textbook example of the distance between animal biology and human medicine. The next few years will be decisive in a narrow, testable sense: whether gene therapy or protein replacement can safely and reliably raise Klotho in people. Until that is demonstrated, Klotho should be understood as a well-validated biological factor and a promising drug target — not as an available therapy.

Sources and Key Research Centers

1. Kuro-o M, Matsumura Y, Aizawa H, et al. «Mutation of the mouse klotho gene leads to a syndrome resembling ageing.» Nature, 1997; 390(6655): 45-51. DOI: 10.1038/36285
2. Kurosu H, Yamamoto M, Clark JD, et al. «Suppression of aging in mice by the hormone Klotho.» Science, 2005; 309(5742): 1829-1833. DOI: 10.1126/science.1112766 — Lifespan extension by overexpression.
3. Dubal DB, Yokoyama JS, Zhu L, et al. «Life extension factor klotho enhances cognition.» Cell Reports, 2014; 7(4): 1065-1076. DOI: 10.1016/j.celrep.2014.03.076
4. Roig-Soriano J, Edo A, Verdes S, et al. «Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience.» Molecular Therapy, 2025; 33(4): 1449-1465. DOI: 10.1016/j.ymthe.2025.02.030 — AAV-mediated secreted Klotho and lifespan in mice.
5. ClinicalTrials.gov: Injectable Klotho plasmid gene therapy in humans (NCT07216781) — Phase 1, single-group study in healthy adults.
6. ClinicalTrials.gov — Registered human studies involving Klotho biology. (Search terms: Klotho cognition, Klotho kidney, alpha-Klotho gene therapy).
7. National Institute on Aging (NIA), U.S. National Institutes of Health — Support for fundamental research on Klotho/FGF23 signalling and aging biology.